Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrumSu Yeon Park, Eun Hee Sohn, Kyong Jin Shin et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 18
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South KoreaSu‐Hyun Kim, Ho Jin Kim, Ju‐Hong Min et al.|Journal of Clinical Neurology|2025Cited by 11
Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated diseaseYou‐Ri Kang, Hyunjin Ju, Ki Hoon Kim et al.|Multiple Sclerosis Journal|2025Cited by 5
Potential prognostic value of rheumatoid factor in anti-aquaporin 4-immunoglobin G-positive neuromyelitis optica spectrum disordersHye Lim Lee, Jin Myoung Seok, Soon-Young Hwang et al.|Journal of the Neurological Sciences|2024Cited by 2
Impact of COVID-19 Infection and Its Association With Previous Vaccination in Patients With Myasthenia Gravis in Korea: A Multicenter Retrospective StudyHee Jo Han, Ha Young Shin, Seung Woo Kim et al.|Journal of Korean Medical Science|2024Cited by 2